GI Dynamics Announces EndoBarrier Positive Study Results

May 22, 2015

GI Dyanmics’ EndoBarrier therapy is significantly close to glucose metabolism improvement achieved with gastric bypass surgery in obese and type 2 diabetes patients, the Lexington, Mass., devicemaker announced Tuesday. The company presented clinical trial data supporting this claim at the American Gastroenterological Association’s annual meeting in Washington, D.C.

The EndoBarrier device is the first endoscopically delivered therapy for obese and uncontrolled type 2 diabetic patients, the company says. The system is designed to mimic the duodenal-jejunal exclusion created by gastric bypass surgery, but with less invasive methods.

Preliminary trial data points to comparable diabetes remission rates and impacts on body weight when compared to the standard of care.

EndoBarrier has been designated for investigational use only in the U.S. The device is CE Mark-approved and is commercially available in Australia and other territories. — Jason Scott